Inquiry Basket
Enfortumab vedotin-ejfv is a first-in-class monoclonal antibody drug conjugate that binds Nectin-4, a protein expressed on bladder cancer cells, and delivers the tubulin toxin, monomethyl auristatin E, into the cell causing cell death. Enfortumab vedotin-ejfv was approved by FDA for the treatment of locally advanced or metastatic urothelial cancer.
| Catalog Number | Size | Price | Quantity |
|---|---|---|---|
| BADC-01596 | -- | $-- |
Enfortumab vedotin-ejfv represents a significant advancement in the realm of cancer therapeutics as a first-in-class monoclonal antibody-drug conjugate (ADC). Its unique mechanism of action is predicated on the specific targeting of Nectin-4, a protein abundantly expressed on the surface of bladder cancer cells. By leveraging this specificity, Enfortumab vedotin-ejfv is able to deliver its cytotoxic payload, monomethyl auristatin E, directly into cancer cells, thereby minimizing systemic exposure and reducing collateral damage to healthy cells. Such precision in targeting epitomizes the strides made in personalized medicine, where treatments are increasingly tailored to the molecular profile of a patient’s cancer, thus enhancing treatment efficacy and improving patient outcomes.
The conjugation of the monoclonal antibody with the potent microtubule-disrupting agent, monomethyl auristatin E, underlines the therapeutic prowess of Enfortumab vedotin-ejfv. By infiltrating cancer cells and interrupting their microtubule networks, this drug induces cell cycle arrest and apoptosis, ultimately leading to tumor cell death. This method of drug delivery ensures that the cytotoxic agent is released in the vicinity of the tumor after internalization, maximizing tumor suppression while sparing normal cells. This aspect of targeted therapy is key in oncology, as it not only enhances the efficacy of cancer treatment but also plays a crucial role in reducing the significant side effects often associated with traditional chemotherapy regimens.
Enfortumab vedotin-ejfv’s approval by the FDA for treating locally advanced or metastatic urothelial cancer marks a pivotal moment in the drug discovery landscape, particularly for patients who have limited treatment options. This approval underscores its importance as an innovative therapeutic option, providing hope for improved survival rates and quality of life for patients afflicted by this aggressive cancer type. Enfortumab vedotin-ejfv is particularly noteworthy for its effectiveness after the failure of platinum-based chemotherapy or immune checkpoint inhibitors, establishing it as a crucial second or third-line treatment option in the therapeutic arsenal against urothelial carcinoma.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
